Search

Your search keyword '"Goetze K"' showing total 137 results

Search Constraints

Start Over You searched for: Author "Goetze K" Remove constraint Author: "Goetze K"
137 results on '"Goetze K"'

Search Results

1. Magnetotransport of single crystal Sm$_2$Ir$_2$O$_7$ across the pressure-induced quantum-critical phase boundary

2. Pressure-induced shift of effective Ce valence, Fermi energy and phase boundaries in CeOs$_4$Sb$_{12}$

3. Monopole density and antiferromagnetic domain control in spin-ice iridates

4. Superconductivity and the upper critical field in the chiral noncentrosymmetric superconductor NbRh$_{2}$B$_{2}$

5. Unusual phase boundary of the magnetic-field-tuned valence transition in CeOs$_4$Sb$_{12}$

6. Fermi-surface topology of the heavy-fermion system Ce$_{2}$PtIn$_{8}$

7. Fermi surface reconstruction and dimensional topology change in Nd-doped CeCoIn$_5$

8. Multigap Superconductivity in Chiral Noncentrosymmetric TaRh$_{2}$B$_{2}$

9. Quasi-two-dimensional Fermi surfaces with localized $f$ electrons in the layered heavy-fermion compound CePt$_2$In$_7$

10. Drastic change of the Fermi surface across the metamagnetic transition in CeRh$_2$Si$_2$

11. Quasi-two-dimensional Fermi surfaces of the heavy-fermion superconductor Ce$_2$PdIn$_8$

12. All-diamond optical assemblies for a beam-multiplexing X-ray monochromator at the Linac Coherent Light Source

18. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS

19. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

20. P045 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?

23. Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B

24. Stratification of Postremission Therapy in Patients with Acute Myeloid Leukemia < 60 Years According to the Karyotype: Results of the German Multicenter Treatment Trials AML HD93 and AML HD98-A

26. P17 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: MUTATIONAL PROFILING OF CLONAL HEMATOPOIESIS, MDS AND SAML DEPICTS DIVERSITIES OF CLONAL PROGRESSION

28. A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma

29. Proof of the recomine-concept

34. 1553TiP A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma

35. P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)

38. OP0151 Docosahexaenoic acid treatment of rheumatoid arthritis: a randomized, double-blind, placebo-controlled, cross-over study

40. Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents

42. DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapy

43. Clinical outcome in older AML patients not fit for intensive chemotherapy: Results of the population-based AMLSG-BiO (NCT01252485) registry study of the German-Austrian AML study group

44. DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): monitoring of minimal residual disease (MRD). A study of the AML Study Group (AMLSG)

46. Moderated Poster Session 4: Monday 4 May 2015, 15:30-16:30 * Room: Moderated Poster Area

47. 27 BLOCKADE OF BCL-2 PROTEINS EFFICIENTLY INDUCES APOPTOSIS IN PROGENITOR CELLS OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS

48. 81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES

Catalog

Books, media, physical & digital resources